Pemetrexed safety and pharmacokinetics in patients with third-space fluid

Nicolas J Dickgreber; Jens Benn Sørensen; Luis G Paz-Ares; Tine Kjestrup Schytte; Jane E Latz; Karen B Schneck; Yuan Zheng; José Miguel Sanchez-Torres

doi:10.1158/1078-0432.CCR-09-3324

Pemetrexed safety and pharmacokinetics in patients with third-space fluid

Nicolas J Dickgreber, Jens Benn Sørensen, Luis G Paz-Ares, Tine Kjestrup Schytte, Jane E Latz, Karen B Schneck, Yuan Zheng, José Miguel Sanchez-Torres

27 Citations (Scopus)

Abstract

Pemetrexed is established as first-line treatment with cisplatin for malignant pleural mesothelioma and advanced nonsquamous non-small-cell lung cancer (NSCLC) and as single-agent second-line treatment for nonsquamous NSCLC. Because the structure and pharmacokinetics of pemetrexed are similar to those of methotrexate, and methotrexate is associated with severe toxicity in patients with third-space fluid (TSF), the safety of pemetrexed in patients with TSF was evaluated.

Original language	English
Journal	Clinical Cancer Research
Volume	16
Issue number	10
Pages (from-to)	2872-80
Number of pages	9
ISSN	1078-0432
DOIs	https://doi.org/10.1158/1078-0432.CCR-09-3324
Publication status	Published - 15 May 2010

Access to Document

10.1158/1078-0432.CCR-09-3324

Cite this

@article{051c0455aa4f4154bf0a9171936d202b,

title = "Pemetrexed safety and pharmacokinetics in patients with third-space fluid",

abstract = "Pemetrexed is established as first-line treatment with cisplatin for malignant pleural mesothelioma and advanced nonsquamous non-small-cell lung cancer (NSCLC) and as single-agent second-line treatment for nonsquamous NSCLC. Because the structure and pharmacokinetics of pemetrexed are similar to those of methotrexate, and methotrexate is associated with severe toxicity in patients with third-space fluid (TSF), the safety of pemetrexed in patients with TSF was evaluated.",

author = "Dickgreber, {Nicolas J} and S{\o}rensen, {Jens Benn} and Paz-Ares, {Luis G} and Schytte, {Tine Kjestrup} and Latz, {Jane E} and Schneck, {Karen B} and Yuan Zheng and Sanchez-Torres, {Jos{\'e} Miguel}",

year = "2010",

month = may,

day = "15",

doi = "10.1158/1078-0432.CCR-09-3324",

language = "English",

volume = "16",

pages = "2872--80",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "10",

}

TY - JOUR

T1 - Pemetrexed safety and pharmacokinetics in patients with third-space fluid

AU - Dickgreber, Nicolas J

AU - Sørensen, Jens Benn

AU - Paz-Ares, Luis G

AU - Schytte, Tine Kjestrup

AU - Latz, Jane E

AU - Schneck, Karen B

AU - Zheng, Yuan

AU - Sanchez-Torres, José Miguel

PY - 2010/5/15

Y1 - 2010/5/15

N2 - Pemetrexed is established as first-line treatment with cisplatin for malignant pleural mesothelioma and advanced nonsquamous non-small-cell lung cancer (NSCLC) and as single-agent second-line treatment for nonsquamous NSCLC. Because the structure and pharmacokinetics of pemetrexed are similar to those of methotrexate, and methotrexate is associated with severe toxicity in patients with third-space fluid (TSF), the safety of pemetrexed in patients with TSF was evaluated.

AB - Pemetrexed is established as first-line treatment with cisplatin for malignant pleural mesothelioma and advanced nonsquamous non-small-cell lung cancer (NSCLC) and as single-agent second-line treatment for nonsquamous NSCLC. Because the structure and pharmacokinetics of pemetrexed are similar to those of methotrexate, and methotrexate is associated with severe toxicity in patients with third-space fluid (TSF), the safety of pemetrexed in patients with TSF was evaluated.

U2 - 10.1158/1078-0432.CCR-09-3324

DO - 10.1158/1078-0432.CCR-09-3324

M3 - Journal article

C2 - 20460481

SN - 1078-0432

VL - 16

SP - 2872

EP - 2880

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 10

ER -

Pemetrexed safety and pharmacokinetics in patients with third-space fluid

Abstract

Access to Document

Fingerprint

Cite this